<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ISOXSUPRINE HYDROCHLORIDE</span><br/>(eye-sox'syoo-preen)<br/><span class="topboxtradename">Vasodilan, </span><span class="topboxtradename">Vasoprine<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic agonist</span>; <span class="classification">vasodilator</span><br/><b>Prototype: </b>Albuterol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Sympathomimetic with beta-adrenergic stimulant activity and with slight effect on alpha receptors. Vasodilating action on
         arteries within skeletal muscles is greater than on cutaneous vessels. Also causes cardiac stimulation and may produce bronchodilation,
         mild inhibition of GI motility, and uterine relaxation.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Has both cerebral and peripheral vasodilatory properties.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy in treatment of cerebral vascular insufficiency and peripheral vascular disease, such as arteriosclerosis
         obliterans, thromboangitis obliterans (Buerger's disease), and Raynaud's disease.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Dysmenorrhea and threatened abortion and premature labor, but efficacy has not been established.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Immediately postpartum; presence of arterial bleeding; parenteral use in presence of hypotension, tachycardia. Safe use in
         pregnancy (category C) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Bleeding disorders; severe cerebrovascular disease, severe obliterative coronary artery disease, recent MI.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Cerebral Vascular Insufficiency, Peripheral Vascular Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1020 mg t.i.d. or q.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>When used with premature labor: Do not give immediately after delivery because it causes uterine relaxation, or in the presence
            of arterial bleeding.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Flushing, orthostatic hypotension with light-headedness, faintness; palpitation, tachycardia. <span class="typehead">CNS:</span> Dizziness, nervousness, trembling, weakness. <span class="typehead">GI:</span> Nausea, vomiting, abdominal distress, abdominal distention. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Duration:</span> 3 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in blood. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1.25 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: Response to treatment of peripheral vascular disorders may take several weeks. Evaluate
            clinical manifestations of arterial insufficiency.
         </li>
<li>Monitor BP and pulse; may cause hypotension and tachycardia. Supervise ambulation.</li>
<li>Observe both mother and baby for hypotension and irregular and rapid heartbeat if isoxsuprine is used to delay premature labor.
            Hypocalcemia, hypoglycemia, and ileus have been observed in babies born of mothers taking isoxsuprine.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of adverse reactions (skin rash, palpitation, flushing) promptly; symptoms are usually effectively controlled
            by dosage reduction or discontinuation of drug.
         </li>
<li>Prevent orthostatic hypotension by making position changes slowly and in stages, particularly from lying down to sitting upright
            and avoid standing still.
         </li>
<li> 							Note: For treatment of menstrual cramps, isoxsuprine is usually started 13 d before onset of menstruation and continued until
            pain is relieved or menstrual flow stops. 						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>